Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Difelikefalin [KORSUVA] as a treatment for pruritis in patients with mild-to-moderate atopic dermatitis (AD)

Next Previous
Search
Trial Profile

A Phase III Difelikefalin [KORSUVA] as a treatment for pruritis in patients with mild-to-moderate atopic dermatitis (AD)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Difelikefalin (Primary) ; Corticosteroids
  • Indications Atopic dermatitis; Pruritus
  • Focus Registrational; Therapeutic Use
  • Acronyms KIND 2

    • Most Recent Events

    • 18 Dec 2023 According to Cara Therapeutics media release, based on outcomes from the dose-finding Part A of the KIND-1 trial the company has decided to discontinue its clinical program in pruritus associated with atopic dermatitis
    • 18 Dec 2023 Status changed from recruiting to discontinued, according to Cara Therapeutics media release.
    • 07 Nov 2022 According to a Cara Therapeutics media release, at the end of the KIND 1 Part A 12-week treatment period, the Company expects to have an internal data readout to inform the dose and sample size to initiate KIND 1 Part B and KIND 2. The internal readout for KIND 1 Part A is expected in the second half of 2023 and topline results are expected in the first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top